|
TorreyPines Therapeutics Inc: Premium Company ProfilePublished by: Datamonitor Published: Apr. 22, 2008 - 47 Pages Table of Contents
AbstractIntroductionTorreyPines Therapeutics is a San-Diego-based biotechnology company formed through a reverse-merger with publicly-held Axonyx in October 2006. Previously known as Neurogenetics, TorreyPines is focused on the discovery and development of novel drug candidates to treat diseases such as chronic pain, migraine, and cognitive disorders. Scope Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies Highlights The company's clinical product pipeline folio includes: Phenserine being developed for Alzheimer’s disease (Phase III); Tezampanel for migraine (Phase II); NGX267 for CIAS (Phase I) and dry mouth (Phase II); NGX426 for migraine (Phase I) and neuropathic pain (Phase I); and Posiphen for Alzheimer’s disease (Phase I). The company recognizes revenues in the form license fees and research funding from its collaborators pursuant to the agreements entered. These primarily include: revenues received from Eisai for the discovery of genes responsible for late onset Alzheimer's disease, and from Life Science Research Israel (LSRI) for the development NGX292 indicated for Alzheimer disease. Reasons to Purchase Access all the important information and analysis on the company in a single report Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company’s adjusted five year financial data along with key ratios and market capitalization . Please note: This is delivered as a Zip file. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||